ClinicalTrials.gg
Active, not recruitingNCT05735119RAISEUpdated May 22, 2026

Embody Post-Market Clinical Follow-Up Study

An observational study in Tendon Injuries- Subscapularis, sponsored by Zimmer Biomet. Active, not recruiting at 5 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Zimmer Biomet · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
100
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 23 studies in Tendon Injuries with a site in United States — 4 open to participants now, 7 under way, none of them phase 3. Tendon Injuries · United States.

Started
2022
with 1 other
Observational
5 of 23
2 open now
Registered
19th of 23
by date

Among the 23 studies in Tendon Injuries with a site in United States, this one is one of 2 that started in 2022, is one of 5 observational ones, and was the 19th registered.

Tendon Injuries

101 studies on the registry are indexed under Tendon Injuries; 28 are open to participants now.

Browse Tendon Injuries studies →

Open to participants now

4 of the 23 studies in Tendon Injuries with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Tendon Injuries studies recruiting now, 5 (42%) set no upper age limit and 7 (58%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Tendon Injuries with a site in United States, or all of them as a file.
02

Study summary

A multi-center, prospective post-market clinical follow-up study: subscapularis repair augmented with Tapestry Biointegrative Implant after shoulder arthroplasty. The primary objective of this study is to evaluate the long-term integrity of the subscapularis tendon repair after shoulder arthroplasty augmented with Tapestry Biointegrative Implant, assessed by ultrasound 6 months postoperatively. Secondary objectives are to assess shoulder function (internal rotation strength), safety, and patient reported outcomes. Patients will be evaluated preoperatively, at the time of surgery, 3, 6, 12 and 24 months after surgery.

Read the detailed description

The proposed investigation is a multi-center, prospective patient registry: subscapularis repair augmented with TAPESTRY® Biointegrative Implant after shoulder arthroplasty. The primary objective of this study is to evaluate the long-term integrity of the subscapularis tendon repair after shoulder arthroplasty augmented with TAPESTRY Biointegrative Implant, assessed by ultrasound 6 months postoperatively. Secondary objectives are to assess shoulder function (internal rotation strength), safety, and patient reported outcomes. Patients will be evaluated preoperatively, at the time of surgery, 3, 6, 12 and 24 months after surgery. A total of 100 patients will be enrolled. Enrolled subjects will include adults undergoing shoulder arthroplasty, who meet the study eligibility criteria. The Tapestry Biointegrative Implant was FDA 510(k) cleared (K201572) on October 22, 2020, for the management and protection of tendon injuries in which there has been no substantial loss of tendon tissue. The primary analysis of subscapularis tendon repair integrity assessed by ultrasound will occur when all study subjects reach 6 months post-surgery. The goal of the analysis is to show that the tendon failure rate for subscapularis repair with Tapestry is lower than the failure rate for subscapularis repair without Tapestry a receiving surgery with the Tapestry and the literature-defined failure rate for tendon healing. Secondary endpoints will be analyzed when the last subject reaches the 24 month timepoint.

03

Conditions studied

  • Tendon Injuries- Subscapularis

Browse trials for

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults undergoing shoulder arthroplasty, who meet the study eligibility criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult, 21 years and older.
  2. Patient requires shoulder arthroplasty (anatomic or reverse) with subscapularis repair due to osteoarthritis, rotator cuff injury, rheumatoid arthritis and/or other inflammatory disorder, osteonecrosis, and/or post-traumatic injury (e.g., humerus fractures).
  3. Patients healthy enough to undergo primary anatomic or reverse shoulder arthroplasty, in the opinion of the investigator;
  4. Patients receiving shoulder arthroplasty with anticipated subscapularis tenotomy (ST) or subscapularis peel (SP).
  5. Intact rotator cuff including subscapularis tendon for anatomic shoulder arthroplasty or a repairable subscapularis tendon for reverse shoulder arthroplasty, as determined by preoperative examination or imaging, if indicated or available preoperatively. Imaging is not required for this assessment.
  6. Ability and willingness to comply with prescribed post-operative rehabilitation program.
  7. Ability and willingness to comply with follow-up visit schedule.
  8. Able to understand the process, including regulatory requirements such as HIPAA authorization, and document informed consent prior to completion of any study-related procedures.
  9. Ability to read, understand, and complete subject-reported outcomes in English.

Exclusion criteria

Exclusion Criteria:

  1. Shoulder arthroplasty requiring a lesser tuberosity osteotomy or revision arthroplasty.
  2. Prior index shoulder surgery requiring treatment to the subscapularis.
  3. Intraoperative identification of irreparable subscapularis tear (rTSA)
  4. Diabetic patients with (HbA1c) level >8% prior to surgery.
  5. Patients with inflammatory arthritis or patients that are , or patients that have a glenoid deficiency.
  6. Patients with a known history of to bovine-derived materials.
  7. Hypersensitivity to poly(D,L-lactide) materials.
  8. Females of who are pregnant or plan to become pregnant during the course of the study.
  9. Currently involved in any injury litigation or worker's compensation claims relating to the index shoulder.
  10. Enrolled, or plans to enroll, in another clinical trial during this study that would affect the outcomes of this study.
  11. History of non-compliance with medical treatment, physical therapy/rehabilitation, or clinical study participation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
24 Months
Patient registry
Yes

Groups and cohorts

  • Subscapularis Tendon Injuries

    Tapestry Biointegrative Implant

    Device: Tapestry Biointegrative Implant

Interventions

  • DeviceTapestry Biointegrative Implant

    Collagen-based implant composed of type I bovine collagen and poly(D,L-lactide). It is designed to function as a non-constricting, protective layer between the tendon and surrounding tissues. Preclinical studies of the Tapestry implant showed dense collagenous fibrous connective tissue ingrowth into and around the implant.

06

What researchers measure

Primary outcomes

  1. Subscapularis repair integrity

    Assessed by ultrasound evaluation per the EMBODY-003 ultrasound procedure manual.

    Time frame: 6 months postoperatively

Secondary outcomes

  1. Subscapularis tendon tissue quality

    Assessed using ultrasound to evaluate and measure thickness compared to normal (9, 10) subscapularis tendon thickness at 6-months postoperatively. Tendon tissue thickness and quality evaluation will be measured by trained personnel per the EMBODY-003 ultrasound procedure manual.

    Time frame: 6 months postoperatively

  2. Internal rotation strength in the belly-press (11,12) position, measured by an electronic handheld dynamometer.

    Subscapularis repair integrity

    Time frame: Screening visit/3 months postoperatively/6 months postoperatively/12 months postoperatively/24 months postoperatively

  3. Subscapularis repair integrity

    Assessed by internal rotation strength in the Bear-Hug position.

    Time frame: Screening visit/3 months postoperatively/6 months postoperatively/12 months postoperatively/24 months postoperatively

  4. Adverse events

    Procedure and/or treatment

    Time frame: Surgery visit/3 months postoperatively/6 months postoperatively/12 months postoperatively/24 months postoperatively

  5. Serious adverse events

    Procedure and/or treatment

    Time frame: Surgery visit/3 months postoperatively/6 months postoperatively/12 months postoperatively/24 months postoperatively

  6. Serious adverse events necessitating a second surgical intervention (SSI)

    Procedure and/or treatment

    Time frame: Surgery visit/3 months postoperatively/6 months postoperatively/12 months postoperatively/24 months postoperatively

  7. Patient Questionnaire

    Patient Satisfaction

    Time frame: 3 months postoperatively/6 months postoperatively/12 months postoperatively/24 months postoperatively

  8. Forward evaluation

    Active Range of Motion (ROM)

    Time frame: Screening visit/3 months postoperatively/6 months postoperatively/12 months postoperatively/24 months postoperatively

  9. Abduction

    Active ROM

    Time frame: Screening visit/3 months postoperatively/6 months postoperatively/12 months postoperatively/24 months postoperatively

  10. External rotation

    Active ROM

    Time frame: Screening visit/3 months postoperatively/6 months postoperatively/12 months postoperatively/24 months postoperatively

  11. Internal rotation

    Active ROM

    Time frame: Screening visit/3 months postoperatively/6 months postoperatively/12 months postoperatively/24 months postoperatively

  12. American Shoulder and Elbow Surgeon Evaluation (ASES)

    Patient reported clinical outcome scores

    Time frame: Baseline/3 months/6 months/12 months/24 months postoperatively

  13. Visual Analog Scale (VAS)

    Patient reported clinical outcome scores

    Time frame: Screening visit/3 months postoperatively/6 months postoperatively/12 months postoperatively/24 months postoperatively

  14. Simple Shoulder Test (SST)

    Patient reported clinical outcome scores

    Time frame: Screening visit/3 months postoperatively/6 months postoperatively/12 months postoperatively/24 months postoperatively

07

Study locations

5 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2022 (actual). Primary completion is estimated for Nov 2026, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2023
First posted
Feb 21, 2023
StartActual
Nov 9, 2022
Primary completionEst.
Nov 2026
CompletionEst.
Jun 2028
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05735119
Lead sponsor
Zimmer Biomet
Responsible party
Sponsor
First posted
Feb 21, 2023
Start date
Nov 9, 2022
Primary completion
Nov 2026 (estimated)
Completion
Jun 2028 (estimated)
Last update
May 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion